IRIS
DI RAIMONDO, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 21.916
EU - Europa 9.808
AS - Asia 8.744
SA - Sud America 1.709
AF - Africa 670
OC - Oceania 29
Continente sconosciuto - Info sul continente non disponibili 19
Totale 42.895
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 20.948
SG - Singapore 4.413
CN - Cina 3.169
IE - Irlanda 2.646
IT - Italia 2.475
UA - Ucraina 2.389
BR - Brasile 1.546
CA - Canada 865
RU - Federazione Russa 688
CI - Costa d'Avorio 406
DE - Germania 313
SE - Svezia 310
IN - India 249
GB - Regno Unito 234
KR - Corea 213
VN - Vietnam 183
SN - Senegal 139
FR - Francia 110
FI - Finlandia 108
CH - Svizzera 87
NL - Olanda 82
UZ - Uzbekistan 77
PL - Polonia 68
BD - Bangladesh 65
MX - Messico 62
AT - Austria 61
JP - Giappone 51
CZ - Repubblica Ceca 50
AR - Argentina 49
BE - Belgio 46
GR - Grecia 44
ZA - Sudafrica 44
IQ - Iraq 42
TR - Turchia 40
LB - Libano 36
HK - Hong Kong 34
ES - Italia 29
EC - Ecuador 26
MA - Marocco 26
VE - Venezuela 24
AU - Australia 20
PK - Pakistan 20
IR - Iran 19
EU - Europa 18
CO - Colombia 17
IL - Israele 17
JO - Giordania 15
BO - Bolivia 13
SA - Arabia Saudita 13
PY - Paraguay 12
AE - Emirati Arabi Uniti 11
CL - Cile 11
KE - Kenya 11
NG - Nigeria 11
RS - Serbia 11
AZ - Azerbaigian 10
BG - Bulgaria 10
KZ - Kazakistan 10
TN - Tunisia 10
DO - Repubblica Dominicana 9
DZ - Algeria 9
LT - Lituania 9
NO - Norvegia 9
RO - Romania 8
EG - Egitto 7
NZ - Nuova Zelanda 7
JM - Giamaica 6
PE - Perù 6
PS - Palestinian Territory 6
TH - Thailandia 6
BH - Bahrain 5
CR - Costa Rica 5
ID - Indonesia 5
KW - Kuwait 5
NP - Nepal 5
OM - Oman 5
SI - Slovenia 5
TT - Trinidad e Tobago 5
BB - Barbados 4
MY - Malesia 4
PH - Filippine 4
UY - Uruguay 4
AL - Albania 3
HN - Honduras 3
LU - Lussemburgo 3
PT - Portogallo 3
AM - Armenia 2
AO - Angola 2
HU - Ungheria 2
KG - Kirghizistan 2
LK - Sri Lanka 2
PA - Panama 2
SV - El Salvador 2
BF - Burkina Faso 1
CW - ???statistics.table.value.countryCode.CW??? 1
DK - Danimarca 1
EE - Estonia 1
ET - Etiopia 1
GA - Gabon 1
GD - Grenada 1
Totale 42.877
Salva come PNG Salva come JPEG
Città #
Santa Clara 2.881
Singapore 2.690
Jacksonville 2.636
Dublin 2.628
Dallas 2.138
Chandler 2.134
Boardman 1.117
Chicago 948
Catania 886
Nanjing 751
Cambridge 720
Andover 716
Lawrence 715
Toronto 644
Ashburn 572
Houston 496
Hefei 454
Des Moines 423
Abidjan 404
San Mateo 386
Beijing 275
Nanchang 262
Wilmington 261
Civitanova Marche 229
Seoul 213
Los Angeles 200
Saint Petersburg 182
Shenyang 180
Hebei 176
Ottawa 148
Jiaxing 147
Dakar 138
Changsha 134
Florence 131
São Paulo 123
Tianjin 109
Grafing 96
Rome 93
Council Bluffs 92
Kochi 92
Dong Ket 87
New York 75
Munich 71
Milan 65
Moscow 61
Palermo 61
Seattle 59
Washington 57
Brooklyn 56
The Dalles 51
Columbus 46
San Francisco 46
Hangzhou 45
Boston 43
Turku 42
Brussels 41
Hanoi 40
Tokyo 40
Den Haag 39
Rio de Janeiro 39
Helsinki 38
Belo Horizonte 37
Norwalk 37
Kunming 35
Falls Church 32
Hong Kong 31
Pune 31
Warsaw 31
Stockholm 30
Jinan 29
Bremen 28
Montreal 28
Tashkent 28
Johannesburg 27
Lappeenranta 27
Guangzhou 25
Ho Chi Minh City 25
Mumbai 25
Phoenix 25
Porto Alegre 23
Bari 22
Brno 22
Chennai 22
Messina 22
Brasília 21
Ann Arbor 20
Liberty Lake 20
Naples 20
Atlanta 19
Campinas 19
Mexico City 19
Frankfurt Am Main 18
London 18
Redwood City 18
Zhengzhou 18
Curitiba 16
Dhaka 16
Hanover 16
Ningbo 16
Fortaleza 15
Totale 29.653
Salva come PNG Salva come JPEG
Nome #
Prognostic meaning of neutrophil to lymphocyte ratio (NLR) and lymphocyte to monocyte ration (LMR) in newly diagnosed Hodgkin lymphoma patients treated upfront with a PET-2 based strategy 236
Childhood neurofibromatosis type 2 (NF2) and related disorders: From bench to bedside and biologically targeted therapies [Neurofibromatosi tipo 2 (NF2) e sindromi correlate in età infantile: dalla biologia molecolare alla pratica clinica e nuove terapie con farmaci biologici] 224
Baseline factors associated with response to ruxolitinib: An independent study on 408 patients with myelofibrosis 173
α-Lipoic Acid Reduces Iron-induced Toxicity and Oxidative Stress in a Model of Iron Overload 170
Clinical Implications of Discordant Early Molecular Responses in CML Patients Treated with Imatinib 164
Heme oxygenase-1 nuclear translocation regulates bortezomib-induced cytotoxicity and mediates genomic instability in myeloma cells. 147
CXCL12/CXCR4 axis supports mitochondrial trafficking in tumor myeloma microenvironment 143
Ixazomib improves bone remodeling and counteracts sonic hedgehog signaling inhibition mediated by myeloma cells 137
Inhibition of TLR4 signaling affects mitochondrial fitness and overcomes bortezomib resistance in myeloma plasma cells 135
Heme Oxygenase Inhibition Sensitizes Neuroblastoma Cells to Carfilzomib 122
Non ABL-directed inhibitors as alternative treatment strategies for chronic myeloid leukemia 120
Antiproliferative and Antiangiogenic Effects of Punica granatum Juice (PGJ) in Multiple Myeloma (MM) 118
Il Rasario. Semeiotica medica 112
Bortezomib modulates CHIT1 and YKL40 in monocyte-derived osteoclast and in myeloma cells. 110
Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph plus Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification 110
13q14 deletion size and number of deleted cells both influence prognosis in chronic lymphocytic leukemia 109
A PHASE III STUDY OF ENOXAPARIN VERSUS ASPIRIN VERSUS LOW-DOSE WARFARIN AS THROMBOPROPHYLAXIS FOR PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA TREATED UP-FRONT WITH THALIDOMIDE BASED-REGIMENS 108
High BCR-ABL/GUSISlevels at diagnosis of chronic phase CML are associated with unfavorable responses to standard-dose imatinib 108
Hedgehog signaling pathways in multiple myeloma 107
Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases 106
A Phase III Study of Enoxaparin Vs Aspirin as Thromboprophylaxis for Newly Diagnosed Myeloma Patients Treated with Lenalidomide-Based Regimen 106
A novel system for semiautomatic sample processing in chronic myeloid leukaemia: Increasing throughput without impacting on molecular monitoring at time of sars-cov-2 pandemic 105
Mitochondrial Functions, Energy Metabolism and Protein Glycosylation are Interconnected Processes Mediating Resistance to Bortezomib in Multiple Myeloma Cells 105
In-vitro NET-osis induced by COVID-19 sera is associated to severe clinical course in not vaccinated patients and immune-dysregulation in breakthrough infection 105
A MULTICENTRIC STUDY TO EVALUATE THE EFFICACY OF EPOIETIN ZETA (BIOSIMILAR OF EPO ALPHA) IN LOW RISK MYELODISPLASTIC PATIENTS 104
Acute pre-hepatic portal thrombosis: diagnosis and therapy 104
A western blot assay for detecting mutant nucleophosmin (NPM1) proteins in acute myeloid leukaemia 104
A snapshot of asparaginase-induced liver insufficiency. 101
Iron regulates myeloma cell/macrophage interaction and drives resistance to bortezomib 99
High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling 99
NEUTROPHIL TO LYMPHOCYTE RATIO (NLR) IMPROVES THE RISK ASSESSMENT OF ISS STAGING IN NEWLY DIAGNOSED MM PATIENTS TREATED UPFRONT WITH NOVEL AGENTS 98
Monocytic myeloid-derived suppressor cells as prognostic factor in chronic myeloid leukaemia patients treated with dasatinib 98
BCR-ABL1 doubling-times and halving-times may predict CML response to tyrosine kinase inhibitors 98
Alternation of epirubicin and mitoxantrone in CHOP-like regimens retains efficacy and reduces overall toxicity in elderly patients with high and intermediate grade non-Hodgkin lymphomas 97
Mesenchymal stem cells (MSC) promotes tumor microenvironment transformation driving Granulocyte-like Myeloid Derived Suppressor Cells (G-MDSC) activation in Smoldering and Multiple Myeloma patients 97
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 97
Pegylated asparaginase-induced liver injury, a case-based review and data from pharmacovigilance 97
Terapia del mieloma multiplo 96
Absolute Count of Myeloid Derived Suppressor Cells (MDSC) Is Able to Predict the Response to Early-PET In Hodgkin Lymphoma 95
Immune off-target effects of Brentuximab Vedotin in relapsed/refractory Hodgkin Lymphoma 95
TLR4 signaling drives mesenchymal stromal cells commitment to promote tumor microenvironment transformation in multiple myeloma 95
Chk1 Inhibition Restores Inotuzumab Ozogamicin Citotoxicity in CD22-Positive Cells Expressing Mutant p53 95
Clinical outcome of SARS-CoV-2 infections occurring in multiple myeloma patients after vaccination and prophylaxis with tixagevimab/cilgavimab 94
Clinical Benefit of Long-Term Disease Control with Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients 94
BORTEZOMIB INHIBITS OSTEOCLASTOGENESIS AND MODULATE CHIT1 AND YKL40 EXPRESSION 94
Plasticity of High-Density Neutrophils in Multiple Myeloma is Associated with Increased Autophagy via STAT3 94
ABL1-Directed Inhibitors for CML: Efficacy, Resistance and Future Perspectives 94
Bortezomib Could Reduce Cell Viability by Activation of Heme Oxygenase 1 in Multiple Myeloma Cells 93
ARGINASE 1 IS A MARKER OF MYELOID-MEDIATED IMMUNOSUPPRESSION WITH PROGNOSTIC MEANING IN CLASSIC HODGKIN'S LYMPHOMA 92
A PHASE 3, RANDOMIZED CLINICAL STUDY OF AUTOLOGOUS TRANSPLANTATION VS CYCLOPHOSPHAMIDE-LENALIDOMIDE-DEXAMETHASONE AT DIAGNOSIS 92
BCR-ABL residues interacting with ponatinib are critical to preserve the tumorigenic potential of the oncoprotein 92
Efficacy of Dasatinib in a Very Elderly CML Patient Expressing a Rare E13a3 Bcr-Abl1 Fusion Transcript: A Case Report 92
Angiogenic factors (VEGF, bFGF, and HGF) in multiple myeloma: higher levels in bone marrow than in peripheral blood 91
A Phase II Study of Chlorambucil Plus Rituximab Followed by Maintenance Versus Observation In Elderly Patients with Previously Untreated Chronic Lymphocytic Leukemia: Results of the First Interim Analysis 91
Bortezomib Inhibits Osteoclastogenesis and Bone Resorption Through Modulation of CHIT1 and YKL40 Expression 91
A Phase III Study of Double Autotransplantation Incorporating Bortezomib-Thalidomide-Dexamethasone (VTD) or Thalidomide-Dexamethasone (TD) for Multiple Myeloma: Superior Clinical Outcomes with VTD Compared to TD 91
Targeting heme Oxygenase-1 with hybrid compounds to overcome Imatinib resistance in chronic myeloid leukemia cell lines 91
A Real-Life Survey of Venous Thromboembolic Events Occurring in Myeloma Patients Treated in Third Line with Second-Generation Novel Agents 91
SPARC expression in CML is associated to imatinib treatment and to inhibition of leukemia cell proliferation 90
A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study 90
Colony-forming cell assay detecting the co-expression of JAK2 V617F and BCR-ABL1 in the same clone: A case report 90
BCR-ABL Tyrosine Kinase Activity Modulates the Phosphorylation, Localization and Function of Interferon Regulatory Factor 5 (irf-5) in Chronic Myeloid Leukemia (CML) Cells 89
PMN-MDSC and arginase are increased in myeloma and may contribute to resistance to therapy 88
Belantamab Mafodotin and Relapsed/Refractory Multiple Myeloma: This Is Not Game Over 87
Lactate trafficking inhibition restores sensitivity to proteasome inhibitors and orchestrates immuno-microenvironment in multiple myeloma 87
CIRCULATING ARGINASE-1 IN SERUM IS A NOVEL BIO-MARKERIN HODGKIN LYMPHOMA 87
AN INSERTION IN THE BCR-ABL KINASE DOMAIN CONTRIBUTES TO IMATINIB MESYLATE RESISTANCE 87
13q14 Chromosome Deletion Size and Number of Deleted Cells Influence Prognosis In Chronic Lymphocytic Leukemia 87
Cementoplasty in the management of painful extraspinal bone metastases: our experience 86
Angiogenesis in acute myeloid leukemia 85
Impact of the Breakpoint Region on the Leukemogenic Potential and the TKI Responsiveness of Atypical BCR-ABL1 Transcripts 85
Multiple Myeloma Treatment in Real-world Clinical Practice: Results of a Prospective, Multinational, Noninterventional Study 85
A Phase III Study to Compare Melphalan, Prednisone, Lenalidomide (MPR) Versus Melphalan 200 Mg/m2 and Autologous Transplantation (MEL200) In Newly Diagnosed Multiple Myeloma Patients 85
Lymphoma of the cecum: a case report 84
A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol 84
Enhanced Antitumor Activity by the Combination of Dasatinib and Selinexor in Chronic Myeloid Leukemia 83
Suppression of survivin induced by BCR-ABL/JAK2/STAT3 pathway sensitizes imatinib-resistant CML cells to different cytotoxic drugs 83
Effects of second-generation tyrosine kinase inhibitors towards osteogenic differentiation of human mesenchymal cells of healthy donors 83
A population-based study of chronic myeloid leukemia patients treated with imatinib in first line 83
Eventi avversi e trigger C12: Stroke in ospedale 83
A case of high-risk AML in a patient with advanced systemic mastocytosis 82
Unsuccessful dasatinib therapy in a refractory patient with chronic lymphocytic leukemia 82
Uncommon long-term survival in a patient with chronic myeloid leukemia 82
BRIT1/MCPH1 expression in chronic myeloid leukemia and its regulation of the G2/M checkpoint. 82
Analysis of metabolic parameters coming from basal and interim PET in hodgkin lymphoma 82
The apoptotic machinery as a biological complex system: analysis of its omics and evolution, identification of candidate genes for fourteen major types of cancer, and experimental validation in CML and neuroblastoma 82
Bone turnover markers in patients with type 1 Gaucher disease 82
Broad copy neutral-loss of heterozygosity regions and rare recurring copy number abnormalities in normal karyotype-acute myeloid leukemia genomes 81
Optimal Response in a Patient With CML Expressing BCR-ABL1 E6A2 Fusion Transcript With Nilotinib Therapy: A Case Report 81
Vg9Vd2 T Lymphocytes Efficiently Recognize and Kill Zoledronate-Sensitized, Imatinib-Sensitive, and Imatinib-Resistant Chronic Myelogenous Leukemia Cells 80
Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile 80
A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma 80
Emangioma, plasmocitoma e mieloma multiplo del rachide 80
Impact of Different Cell Counting Methods in Molecular Monitoring of Chronic Myeloid Leukemia Patients. 80
Myeloma Patient With Brugada Syndrome and Successful Lenalidomide Treatment 79
Ruxolitinib treatment in myelofibrosis and polycythemia vera causes suboptimal humoral immune response following standard and booster vaccination with BNT162b2 mRNA COVID-19 vaccine 79
Chitotriosidase Expression during Monocyte-Derived Dendritic Cells Differentiation and Maturation 79
Clinico-biological features of 5202 patients with acute lymphoblastic leukemia enrolled in the Italian AIEOP and GIMEMA protocols and stratified in age cohorts. 79
A NEW CYTOGENETIC ABNORMALITY, T(1;4) (P22;P16) IN AML M4 PATIENT AFTER CHEMOTHERAPY TREATMENT 79
Antitumor activity of bortezomib alone and in combination with TRAIL in human acute myeloid leukemia 79
Totale 9.927
Salva come PNG Salva come JPEG
Categoria #
all - tutte 177.904
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 177.904
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.526 0 0 564 81 1.175 67 540 13 470 8 430 178
2021/20225.171 637 763 22 43 872 42 762 175 524 28 122 1.181
2022/20237.429 743 273 104 503 714 1.384 24 1.266 1.976 58 274 110
2023/20243.154 209 432 133 251 142 514 68 206 15 86 676 422
2024/202512.800 99 2.090 837 448 2.795 1.044 380 521 1.091 1.399 960 1.136
2025/20265.035 1.673 1.754 1.608 0 0 0 0 0 0 0 0 0
Totale 43.951